Advancing Breast Cancer Prevention: Dr. Quay Discusses Oral Drug Delivery Innovations

In a recent episode of Sit and Deliver, hosted by Tom von Gunden, Chief Editor of Drug Delivery Leader, Dr. Steven Quay, CEO of Atossa Therapeutics, shares groundbreaking insights into the development of orally administered therapies aimed at breast cancer prevention. Highlighting Atossa’s pioneering work with (Z)-endoxifin, Dr. Quay explores how innovative oral drug formulations can effectively reduce breast density, thereby significantly decreasing the risk of breast cancer in high-risk populations. This conversation underscores the critical shift from reactive treatments to proactive prevention, potentially transforming breast cancer outcomes. For a detailed exploration of these promising advancements, watch the full interview and read more at Drug Delivery Leader.